{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:21:00Z","timestamp":1791346860168,"version":"4.3.1"},"reference-count":212,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41569-025-01183-6","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T07:06:19Z","timestamp":1751007979000},"page":"814-831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Tailored therapeutics for cardiomyopathies"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6356-2205","authenticated-orcid":false,"given":"Athanasios","family":"Bakalakos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Monda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3383-3984","authenticated-orcid":false,"given":"Perry Mark","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"1183_CR1","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo, E. et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur. Heart J. 44, 3503\u20133626 (2023).","journal-title":"Eur. Heart J."},{"key":"1183_CR2","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1093\/eurheartj\/ehac543","volume":"43","author":"C Rapezzi","year":"2022","unstructured":"Rapezzi, C. et al. Restrictive cardiomyopathy: definition and diagnosis. Eur. Heart J. 43, 4679\u20134693 (2022).","journal-title":"Eur. Heart J."},{"key":"1183_CR3","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1161\/CIRCULATIONAHA.108.840827","volume":"121","author":"FI Marcus","year":"2010","unstructured":"Marcus, F. I. et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy\/dysplasia: proposed modification of the task force criteria. Circulation 121, 1533\u20131541 (2010).","journal-title":"Circulation"},{"key":"1183_CR4","doi-asserted-by":"publisher","first-page":"131447","DOI":"10.1016\/j.ijcard.2023.131447","volume":"395","author":"D Corrado","year":"2024","unstructured":"Corrado, D. et al. Proposed diagnostic criteria for arrhythmogenic cardiomyopathy: European Task Force consensus report. Int. J. Cardiol. 395, 131447 (2024).","journal-title":"Int. J. Cardiol."},{"key":"1183_CR5","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1038\/s41588-024-01952-y","volume":"56","author":"SL Zheng","year":"2024","unstructured":"Zheng, S. L. et al. Genome-wide association analysis provides insights into the molecular etiology of dilated cardiomyopathy. Nat. Genet. 56, 2646\u20132658 (2024).","journal-title":"Nat. Genet."},{"key":"1183_CR6","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1038\/s41588-024-01975-5","volume":"56","author":"SJ Jurgens","year":"2024","unstructured":"Jurgens, S. J. et al. Genome-wide association study reveals mechanisms underlying dilated cardiomyopathy and myocardial resilience. Nat. Genet. 56, 2636\u20132645 (2024).","journal-title":"Nat. Genet."},{"key":"1183_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41588-020-00764-0","volume":"53","author":"AR Harper","year":"2021","unstructured":"Harper, A. R. et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat. Genet. 53, 135\u2013142 (2021).","journal-title":"Nat. Genet."},{"key":"1183_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jacc.2024.12.010","volume":"85","author":"S Hespe","year":"2025","unstructured":"Hespe, S. et al. Genes associated with hypertrophic cardiomyopathy: a reappraisal by the ClinGen Hereditary Cardiovascular Disease Gene Curation Expert Panel. J. Am. Coll. Cardiol. 85, 727\u2013740 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1183_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.116.001620","volume":"10","author":"J Ingles","year":"2017","unstructured":"Ingles, J. et al. Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications. Circ. Cardiovasc. Genet. 10, e001620 (2017).","journal-title":"Circ. Cardiovasc. Genet."},{"key":"1183_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.amjcard.2022.06.017","volume":"179","author":"BA Maron","year":"2022","unstructured":"Maron, B. A. et al. What causes hypertrophic cardiomyopathy? Am. J. Cardiol. 179, 74\u201382 (2022).","journal-title":"Am. J. Cardiol."},{"key":"1183_CR11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1161\/CIRCGEN.122.003861","volume":"16","author":"E Monda","year":"2023","unstructured":"Monda, E. et al. Natural history of hypertrophic cardiomyopathy in Noonan syndrome with multiple lentigines. Circ. Genom. Precis. Med. 16, 350\u2013358 (2023).","journal-title":"Circ. Genom. Precis. Med."},{"key":"1183_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ijcard.2022.03.050","volume":"357","author":"G Limongelli","year":"2022","unstructured":"Limongelli, G. et al. Diagnosis and management of rare cardiomyopathies in adult and paediatric patients. A position paper of the Italian Society of Cardiology (SIC) and Italian Society of Paediatric Cardiology (SICP). Int. J. Cardiol. 357, 55\u201371 (2022).","journal-title":"Int. J. Cardiol."},{"key":"1183_CR13","first-page":"754","volume":"40","author":"A Bakalakos","year":"2024","unstructured":"Bakalakos, A., Monda, E. & Elliott, P. M. The diagnostic and therapeutic implications of phenocopies and mimics of hypertrophic cardiomyopathy. Can. J. Cardiol. 40, 754\u2013765 (2024).","journal-title":"Can. J. Cardiol."},{"key":"1183_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.120.053033","volume":"144","author":"E Jordan","year":"2021","unstructured":"Jordan, E. et al. Evidence-based assessment of genes in dilated cardiomyopathy. Circulation 144, 7\u201319 (2021).","journal-title":"Circulation"},{"key":"1183_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.122.003704","volume":"15","author":"M Bourfiss","year":"2022","unstructured":"Bourfiss, M. et al. Prevalence and disease expression of pathogenic and likely pathogenic variants associated with inherited cardiomyopathies in the general population. Circ. Genom. Precis. Med. 15, e003704 (2022).","journal-title":"Circ. Genom. Precis. Med."},{"key":"1183_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMoa1110186","volume":"366","author":"DS Herman","year":"2012","unstructured":"Herman, D. S. et al. Truncations of titin causing dilated cardiomyopathy. N. Engl. J. Med. 366, 619\u2013628 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1183_CR17","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1002\/ejhf.3470","volume":"26","author":"E Monda","year":"2024","unstructured":"Monda, E. et al. Aetiology and clinical manifestations of patients with non-dilated left ventricular cardiomyopathy. Eur. J. Heart Fail. 26, 2579\u20132581 (2024).","journal-title":"Eur. J. Heart Fail."},{"key":"1183_CR18","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/ejhf.1534","volume":"21","author":"PM Elliott","year":"2019","unstructured":"Elliott, P. M. et al. Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. Eur. J. Heart Fail. 21, 955\u2013964 (2019).","journal-title":"Eur. J. Heart Fail."},{"key":"1183_CR19","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1161\/CIRCULATIONAHA.119.044934","volume":"141","author":"ED Smith","year":"2020","unstructured":"Smith, E. D. et al. Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. Circulation 141, 1872\u20131884 (2020).","journal-title":"Circulation"},{"key":"1183_CR20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/europace\/euab183","volume":"24","author":"W Wang","year":"2022","unstructured":"Wang, W. et al. Clinical characteristics and risk stratification of desmoplakin cardiomyopathy. Europace 24, 268\u2013277 (2022).","journal-title":"Europace"},{"key":"1183_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.118.002373","volume":"11","author":"K Reichl","year":"2018","unstructured":"Reichl, K., Kreykes, S. E., Martin, C. M. & Shenoy, C. Desmoplakin variant-associated arrhythmogenic cardiomyopathy presenting as acute myocarditis. Circ. Genom. Precis. Med. 11, e002373 (2018).","journal-title":"Circ. Genom. Precis. Med."},{"key":"1183_CR22","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1161\/CIRCRESAHA.117.309345","volume":"121","author":"D Corrado","year":"2017","unstructured":"Corrado, D., Basso, C. & Judge, D. P. Arrhythmogenic cardiomyopathy. Circ. Res. 121, 784\u2013802 (2017).","journal-title":"Circ. Res."},{"key":"1183_CR23","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/eurheartj\/ehaa141","volume":"41","author":"CA James","year":"2020","unstructured":"James, C. A., Syrris, P., van Tintelen, J. P. & Calkins, H. The role of genetics in cardiovascular disease: arrhythmogenic cardiomyopathy. Eur. Heart J. 41, 1393\u20131400 (2020).","journal-title":"Eur. Heart J."},{"key":"1183_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/srep41387","volume":"7","author":"Z Xu","year":"2017","unstructured":"Xu, Z. et al. Genotype-phenotype relationship in patients with arrhythmogenic right ventricular cardiomyopathy caused by desmosomal gene mutations: a systematic review and meta-analysis. Sci. Rep. 7, 41387 (2017).","journal-title":"Sci. Rep."},{"key":"1183_CR25","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/nature03920","volume":"436","author":"JL Woodhead","year":"2005","unstructured":"Woodhead, J. L. et al. Atomic model of a myosin filament in the relaxed state. Nature 436, 1195\u20131199 (2005).","journal-title":"Nature"},{"key":"1183_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.8316858","volume":"261","author":"I Rayment","year":"1993","unstructured":"Rayment, I. et al. Structure of the actin-myosin complex and its implications for muscle contraction. Science 261, 58\u201365 (1993).","journal-title":"Science"},{"key":"1183_CR27","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1016\/j.bpj.2011.02.061","volume":"100","author":"P Hooijman","year":"2011","unstructured":"Hooijman, P., Stewart, M. A. & Cooke, R. A new state of cardiac myosin with very slow ATP turnover: a potential cardioprotective mechanism in the heart. Biophys. J. 100, 1969\u20131976 (2011).","journal-title":"Biophys. J."},{"key":"1183_CR28","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.jmb.2016.01.027","volume":"428","author":"L Alamo","year":"2016","unstructured":"Alamo, L. et al. Conserved intramolecular interactions maintain myosin interacting-heads motifs explaining tarantula muscle super-relaxed state structural basis. J. Mol. Biol. 428, 1142\u20131164 (2016).","journal-title":"J. Mol. Biol."},{"key":"1183_CR29","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nsmb.3408","volume":"24","author":"S Nag","year":"2017","unstructured":"Nag, S. et al. The myosin mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations. Nat. Struct. Mol. Biol. 24, 525\u2013533 (2017).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1183_CR30","doi-asserted-by":"publisher","first-page":"E165","DOI":"10.1161\/circ.104.25.e165","volume":"104","author":"H Ashrafian","year":"2001","unstructured":"Ashrafian, H. & Watkins, H. Myocardial dysfunction in hypertrophic cardiomyopathy. Circulation 104, E165 (2001).","journal-title":"Circulation"},{"key":"1183_CR31","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/S0735-1097(02)03009-7","volume":"41","author":"JG Crilley","year":"2003","unstructured":"Crilley, J. G. et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J. Am. Coll. Cardiol. 41, 1776\u20131782 (2003).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1183_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41569-018-0044-6","volume":"15","author":"E Bertero","year":"2018","unstructured":"Bertero, E. & Maack, C. Metabolic remodelling in heart failure. Nat. Rev. Cardiol. 15, 457\u2013470 (2018).","journal-title":"Nat. Rev. Cardiol."},{"key":"1183_CR33","doi-asserted-by":"publisher","first-page":"eaat1199","DOI":"10.1126\/scitranslmed.aat1199","volume":"11","author":"CN Toepfer","year":"2019","unstructured":"Toepfer, C. N. et al. Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin. Sci. Transl. Med. 11, eaat1199 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1183_CR34","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.119.042339","volume":"141","author":"CN Toepfer","year":"2020","unstructured":"Toepfer, C. N. et al. Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. Circulation 141, 828\u2013842 (2020).","journal-title":"Circulation"},{"key":"1183_CR35","doi-asserted-by":"publisher","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","volume":"115","author":"RL Anderson","year":"2018","unstructured":"Anderson, R. L. et al. Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc. Natl Acad. Sci. USA 115, E8143\u2013E8152 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1183_CR36","doi-asserted-by":"publisher","first-page":"E7486","DOI":"10.1073\/pnas.1720342115","volume":"115","author":"JA Rohde","year":"2018","unstructured":"Rohde, J. A., Roopnarine, O., Thomas, D. D. & Muretta, J. M. Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin. Proc. Natl Acad. Sci. USA 115, E7486\u2013E7494 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1183_CR37","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nature15727","volume":"528","author":"M Linari","year":"2015","unstructured":"Linari, M. et al. Force generation by skeletal muscle is controlled by mechanosensing in myosin filaments. Nature 528, 276\u2013279 (2015).","journal-title":"Nature"},{"key":"1183_CR38","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ceb.2020.03.001","volume":"63","author":"CS Janota","year":"2020","unstructured":"Janota, C. S., Calero-Cuenca, F. J. & Gomes, E. R. The role of the cell nucleus in mechanotransduction. Curr. Opin. Cell Biol. 63, 204\u2013211 (2020).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1183_CR39","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1056\/NEJM199912023412302","volume":"341","author":"D Fatkin","year":"1999","unstructured":"Fatkin, D. et al. Missense mutations in the rod domain of the lamin A\/C gene as causes of dilated cardiomyopathy and conduction-system disease. N. Engl. J. Med. 341, 1715\u20131724 (1999).","journal-title":"N. Engl. J. Med."},{"key":"1183_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1172\/JCI200419448","volume":"113","author":"V Nikolova","year":"2004","unstructured":"Nikolova, V. et al. Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A\/C-deficient mice. J. Clin. Invest. 113, 357\u2013369 (2004).","journal-title":"J. Clin. Invest."},{"key":"1183_CR41","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/ng0396-254","volume":"12","author":"A Nagano","year":"1996","unstructured":"Nagano, A. et al. Emerin deficiency at the nuclear membrane in patients with Emery\u2013Dreifuss muscular dystrophy. Nat. Genet. 12, 254\u2013259 (1996).","journal-title":"Nat. Genet."},{"key":"1183_CR42","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/hmg\/5.6.801","volume":"5","author":"S Manilal","year":"1996","unstructured":"Manilal, S., Nguyen, T. M., Sewry, C. A. & Morris, G. E. The Emery\u2013Dreifuss muscular dystrophy protein, emerin, is a nuclear membrane protein. Hum. Mol. Genet. 5, 801\u2013808 (1996).","journal-title":"Hum. Mol. Genet."},{"key":"1183_CR43","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/ng1294-323","volume":"8","author":"S Bione","year":"1994","unstructured":"Bione, S. et al. Identification of a novel X-linked gene responsible for Emery\u2013Dreifuss muscular dystrophy. Nat. Genet. 8, 323\u2013327 (1994).","journal-title":"Nat. Genet."},{"key":"1183_CR44","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41580-021-00389-z","volume":"22","author":"JJ Dowling","year":"2021","unstructured":"Dowling, J. J., Weihl, C. C. & Spencer, M. J. Molecular and cellular basis of genetically inherited skeletal muscle disorders. Nat. Rev. Mol. Cell Biol. 22, 713\u2013732 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1183_CR45","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ajhg.2009.07.015","volume":"85","author":"L Gueneau","year":"2009","unstructured":"Gueneau, L. et al. Mutations of the FHL1 gene cause Emery\u2013Dreifuss muscular dystrophy. Am. J. Hum. Genet. 85, 338\u2013353 (2009).","journal-title":"Am. J. Hum. Genet."},{"key":"1183_CR46","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1093\/hmg\/dds157","volume":"21","author":"FW Friedrich","year":"2012","unstructured":"Friedrich, F. W. et al. Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy. Hum. Mol. Genet. 21, 3237\u20133254 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"1183_CR47","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1161\/CIRCULATIONAHA.106.646778","volume":"115","author":"MRG Taylor","year":"2007","unstructured":"Taylor, M. R. G. et al. Prevalence of desmin mutations in dilated cardiomyopathy. Circulation 115, 1244\u20131251 (2007).","journal-title":"Circulation"},{"key":"1183_CR48","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jacep.2024.02.031","volume":"10","author":"FJ Bermudez-Jimenez","year":"2024","unstructured":"Bermudez-Jimenez, F. J. et al. Phenotype and clinical outcomes in desmin-related arrhythmogenic cardiomyopathy. JACC Clin. Electrophysiol. 10, 1178\u20131190 (2024).","journal-title":"JACC Clin. Electrophysiol."},{"key":"1183_CR49","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1161\/CIRCULATIONAHA.116.024599","volume":"135","author":"Y Li","year":"2017","unstructured":"Li, Y. et al. Cardiac fibroblast\u2013specific activating transcription factor 3 protects against heart failure by suppressing MAP2K3\u2013p38 signaling. Circulation 135, 2041\u20132057 (2017).","journal-title":"Circulation"},{"key":"1183_CR50","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1093\/hmg\/dds265","volume":"21","author":"A Muchir","year":"2012","unstructured":"Muchir, A. et al. Abnormal p38 mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by lamin A\/C gene mutation. Hum. Mol. Genet. 21, 4325\u20134333 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"1183_CR51","doi-asserted-by":"publisher","first-page":"144ra102","DOI":"10.1126\/scitranslmed.3003875","volume":"4","author":"JC Choi","year":"2012","unstructured":"Choi, J. C. et al. Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A\/C gene mutation. Sci. Transl. Med. 4, 144ra102 (2012).","journal-title":"Sci. Transl. Med."},{"key":"1183_CR52","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41586-019-1406-x","volume":"572","author":"J Lee","year":"2019","unstructured":"Lee, J. et al. Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy. Nature 572, 335\u2013340 (2019).","journal-title":"Nature"},{"key":"1183_CR53","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.122.003730","volume":"16","author":"CA MacRae","year":"2023","unstructured":"MacRae, C. A. et al. Efficacy and safety of ARRY-371797 in LMNA-related dilated cardiomyopathy: a phase 2 study. Circ. Genom. Precis. Med. 16, e003730 (2023).","journal-title":"Circ. Genom. Precis. Med."},{"key":"1183_CR54","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.011548","volume":"17","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia, P. et al. REALM-DCM: a phase 3, multinational, randomized, placebo-controlled trial of ARRY-371797 in patients with symptomatic LMNA-related dilated cardiomyopathy. Circ. Heart Fail. 17, e011548 (2024).","journal-title":"Circ. Heart Fail."},{"key":"1183_CR55","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCRESAHA.123.322750","volume":"133","author":"X Zhou","year":"2023","unstructured":"Zhou, X. et al. Interaction of filamin C with actin is essential for cardiac development and function. Circ. Res. 133, 400\u2013411 (2023).","journal-title":"Circ. Res."},{"key":"1183_CR56","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1016\/j.jacc.2016.09.927","volume":"68","author":"MF Ortiz-Genga","year":"2016","unstructured":"Ortiz-Genga, M. F. et al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. J. Am. Coll. Cardiol. 68, 2440\u20132451 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1183_CR57","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.121.003645","volume":"15","author":"ED Carruth","year":"2022","unstructured":"Carruth, E. D. et al. Loss-of-function FLNC variants are associated with arrhythmogenic cardiomyopathy phenotypes when identified through exome sequencing of a general clinical population. Circ. Genom. Precis. Med. 15, e003645 (2022).","journal-title":"Circ. Genom. Precis. Med."},{"key":"1183_CR58","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/0735-1097(93)90436-5","volume":"22","author":"M Burch","year":"1993","unstructured":"Burch, M. et al. Cardiologic abnormalities in Noonan syndrome: phenotypic diagnosis and echocardiographic assessment of 118 patients. J. Am. Coll. Cardiol. 22, 1189\u20131192 (1993).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1183_CR59","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.hfc.2021.07.004","volume":"18","author":"M Lioncino","year":"2022","unstructured":"Lioncino, M. et al. Hypertrophic cardiomyopathy in RASopathies: diagnosis, clinical characteristics, prognostic implications, and management. Heart Fail. Clin. 18, 19\u201329 (2022).","journal-title":"Heart Fail. Clin."},{"key":"1183_CR60","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior, I. A., Hood, F. E. & Hartley, J. L. The frequency of Ras mutations in cancer. Cancer Res. 80, 2969\u20132974 (2020).","journal-title":"Cancer Res."},{"key":"1183_CR61","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1172\/JCI44929","volume":"121","author":"X Wu","year":"2011","unstructured":"Wu, X. et al. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J. Clin. Invest. 121, 1009\u20131025 (2011).","journal-title":"J. Clin. Invest."},{"key":"1183_CR62","doi-asserted-by":"publisher","first-page":"16395","DOI":"10.1073\/pnas.1418126111","volume":"111","author":"I Hern\u00e1ndez-Porras","year":"2014","unstructured":"Hern\u00e1ndez-Porras, I. et al. K-RasV14I recapitulates Noonan syndrome in mice. Proc. Natl Acad. Sci. USA 111, 16395\u201316400 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1183_CR63","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.jacc.2019.01.066","volume":"73","author":"G Andelfinger","year":"2019","unstructured":"Andelfinger, G. et al. Hypertrophic cardiomyopathy in Noonan syndrome treated by MEK-inhibition. J. Am. Coll. Cardiol. 73, 2237\u20132239 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1183_CR64","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jacbts.2024.10.002","volume":"10","author":"CM Wolf","year":"2025","unstructured":"Wolf, C. M. et al. Impact of MEK inhibition on childhood RASopathy-associated hypertrophic cardiomyopathy. JACC Basic. Transl. Sci. 10, 152\u2013166 (2025).","journal-title":"JACC Basic. Transl. Sci."},{"key":"1183_CR65","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1152\/physrev.00006.2004","volume":"85","author":"WC Stanley","year":"2005","unstructured":"Stanley, W. C., Recchia, F. A. & Lopaschuk, G. D. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85, 1093\u20131129 (2005).","journal-title":"Physiol. Rev."},{"key":"1183_CR66","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1126\/science.abc8861","volume":"370","author":"D Murashige","year":"2020","unstructured":"Murashige, D. et al. Comprehensive quantification of fuel use by the failing and nonfailing human heart. Science 370, 364\u2013368 (2020).","journal-title":"Science"},{"key":"1183_CR67","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1172\/JCI120849","volume":"128","author":"B Zhou","year":"2018","unstructured":"Zhou, B. & Tian, R. Mitochondrial dysfunction in pathophysiology of heart failure. J. Clin. Invest. 128, 3716\u20133726 (2018).","journal-title":"J. Clin. Invest."},{"key":"1183_CR68","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jacbts.2019.07.009","volume":"5","author":"HN Sabbah","year":"2020","unstructured":"Sabbah, H. N. Targeting the mitochondria in heart failure: a translational perspective. JACC Basic Transl. Sci. 5, 88\u2013106 (2020).","journal-title":"JACC Basic Transl. Sci."},{"key":"1183_CR69","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1161\/01.CIR.92.4.778","volume":"92","author":"M Meyer","year":"1995","unstructured":"Meyer, M. et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 92, 778\u2013784 (1995).","journal-title":"Circulation"},{"key":"1183_CR70","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0092-8674(00)81662-1","volume":"99","author":"S Minamisawa","year":"1999","unstructured":"Minamisawa, S. et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99, 313\u2013322 (1999).","journal-title":"Cell"},{"key":"1183_CR71","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.cardiores.2006.11.005","volume":"73","author":"LS Maier","year":"2007","unstructured":"Maier, L. S. & Bers, D. M. Role of Ca2+\/calmodulin-dependent protein kinase (CaMK) in excitation-contraction coupling in the heart. Cardiovasc. Res. 73, 631\u2013640 (2007).","journal-title":"Cardiovasc. Res."},{"key":"1183_CR72","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/eurjhf\/hfs119","volume":"14","author":"PA van der Zwaag","year":"2012","unstructured":"van der Zwaag, P. A. et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur. J. Heart Fail. 14, 1199\u20131207 (2012).","journal-title":"Eur. J. Heart Fail."},{"key":"1183_CR73","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1093\/eurheartj\/ehab294","volume":"42","author":"TE Verstraelen","year":"2021","unstructured":"Verstraelen, T. E. et al. Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers-reaching the frontiers of individual risk prediction. Eur. Heart J. 42, 2842\u20132850 (2021).","journal-title":"Eur. Heart J."},{"key":"1183_CR74","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1161\/CIRCULATIONAHA.115.020086","volume":"134","author":"AS Helms","year":"2016","unstructured":"Helms, A. S. et al. Genotype-dependent and -independent calcium signaling dysregulation in human hypertrophic cardiomyopathy. Circulation 134, 1738\u20131748 (2016).","journal-title":"Circulation"},{"key":"1183_CR75","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jacbts.2024.02.017","volume":"9","author":"NM Stege","year":"2024","unstructured":"Stege, N. M., de Boer, R. A., Makarewich, C. A., van der Meer, P. & Sillj\u00e9, H. H. W. Reassessing the mechanisms of PLN-R14del cardiomyopathy: from calcium dysregulation to S\/ER malformation. JACC Basic Transl. Sci. 9, 1041\u20131052 (2024).","journal-title":"JACC Basic Transl. Sci."},{"key":"1183_CR76","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3389\/fphys.2018.01391","volume":"9","author":"R Coppini","year":"2018","unstructured":"Coppini, R., Ferrantini, C., Mugelli, A., Poggesi, C. & Cerbai, E. Altered Ca2+ and Na+ homeostasis in human hypertrophic cardiomyopathy: implications for arrhythmogenesis. Front. Physiol. 9, 1391 (2018).","journal-title":"Front. Physiol."},{"key":"1183_CR77","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","volume":"127","author":"R Coppini","year":"2013","unstructured":"Coppini, R. et al. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation 127, 575\u2013584 (2013).","journal-title":"Circulation"},{"key":"1183_CR78","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003565","volume":"10","author":"R Coppini","year":"2017","unstructured":"Coppini, R. et al. Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy. Circ. Heart Fail. 10, e003565 (2017).","journal-title":"Circ. Heart Fail."},{"key":"1183_CR79","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005407","volume":"6","author":"C Ferrantini","year":"2017","unstructured":"Ferrantini, C. et al. Pathogenesis of hypertrophic cardiomyopathy is mutation rather than disease specific: a comparison of the cardiac troponin T E163R and R92Q mouse models. J. Am. Heart Assoc. 6, e005407 (2017).","journal-title":"J. Am. Heart Assoc."},{"key":"1183_CR80","doi-asserted-by":"publisher","first-page":"10487","DOI":"10.1074\/jbc.RA118.002081","volume":"293","author":"P Robinson","year":"2018","unstructured":"Robinson, P. et al. Hypertrophic cardiomyopathy mutations increase myofilament Ca2+ buffering, alter intracellular Ca2+ handling, and stimulate Ca2+-dependent signaling. J. Biol. Chem. 293, 10487\u201310499 (2018).","journal-title":"J. Biol. Chem."},{"key":"1183_CR81","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1093\/cvr\/cvaa124","volume":"116","author":"R Coppini","year":"2020","unstructured":"Coppini, R., Santini, L., Olivotto, I., Ackerman, M. J. & Cerbai, E. Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy. Cardiovasc. Res. 116, 1585\u20131599 (2020).","journal-title":"Cardiovasc. Res."},{"key":"1183_CR82","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1161\/01.CIR.0000139333.83620.5D","volume":"110","author":"C Antzelevitch","year":"2004","unstructured":"Antzelevitch, C. et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110, 904\u2013910 (2004).","journal-title":"Circulation"},{"key":"1183_CR83","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","volume":"11","author":"I Olivotto","year":"2018","unstructured":"Olivotto, I. et al. Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study. Circ. Heart Fail. 11, e004124 (2018).","journal-title":"Circ. Heart Fail."},{"key":"1183_CR84","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1093\/hmg\/9.18.2761","volume":"9","author":"EE Norgett","year":"2000","unstructured":"Norgett, E. E. Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum. Mol. Genet. 9, 2761\u20132766 (2000).","journal-title":"Hum. Mol. Genet."},{"key":"1183_CR85","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1172\/JCI27751","volume":"116","author":"E Garcia-Gras","year":"2006","unstructured":"Garcia-Gras, E. et al. Suppression of canonical Wnt\/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J. Clin. Invest. 116, 2012\u20132021 (2006).","journal-title":"J. Clin. Invest."},{"key":"1183_CR86","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1161\/CIRCRESAHA.114.302810","volume":"114","author":"SN Chen","year":"2014","unstructured":"Chen, S. N. et al. The hippo pathway is activated and is a causal mechanism for adipogenesis in arrhythmogenic cardiomyopathy. Circ. Res. 114, 454\u2013468 (2014).","journal-title":"Circ. Res."},{"key":"1183_CR87","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12265-024-10567-x","volume":"18","author":"BSH Low","year":"2024","unstructured":"Low, B. S. H. & Asimaki, A. Targeting canonical Wnt-signaling through GSK-3\u03b2 in arrhythmogenic cardiomyopathy: conservative or progressive? J. Cardiovasc. Transl. Res. 18, 121\u2013131 (2024).","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"1183_CR88","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06174220 (2025)."},{"key":"1183_CR89","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.yjmcc.2013.10.019","volume":"70","author":"J Davis","year":"2014","unstructured":"Davis, J. & Molkentin, J. D. Myofibroblasts: trust your heart and let fate decide. J. Mol. Cell Cardiol. 70, 9\u201318 (2014).","journal-title":"J. Mol. Cell Cardiol."},{"key":"1183_CR90","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","volume":"573","author":"H Aghajanian","year":"2019","unstructured":"Aghajanian, H. et al. Targeting cardiac fibrosis with engineered T cells. Nature 573, 430\u2013433 (2019).","journal-title":"Nature"},{"key":"1183_CR91","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","volume":"3","author":"A Axelsson","year":"2015","unstructured":"Axelsson, A. et al. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 3, 123\u2013131 (2015).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1183_CR92","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1001\/jamacardio.2023.2808","volume":"8","author":"CR Vissing","year":"2023","unstructured":"Vissing, C. R. et al. Cardiac remodeling in subclinical hypertrophic cardiomyopathy: the VANISH randomized clinical trial. JAMA Cardiol. 8, 1083\u20131088 (2023).","journal-title":"JAMA Cardiol."},{"key":"1183_CR93","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/01.fjc.0000248236.43760.86","volume":"48","author":"MMD Resende","year":"2006","unstructured":"Resende, M. M. D., Kriegel, A. J. & Greene, A. S. Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy. J. Cardiovasc. Pharmacol. 48, 265\u2013273 (2006).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"1183_CR94","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1126\/science.1137325","volume":"316","author":"JB Kim","year":"2007","unstructured":"Kim, J. B. et al. Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. Science 316, 1481\u20131484 (2007).","journal-title":"Science"},{"key":"1183_CR95","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1161\/CIRCRESAHA.117.310221","volume":"121","author":"BH Trachtenberg","year":"2017","unstructured":"Trachtenberg, B. H. & Hare, J. M. Inflammatory cardiomyopathic syndromes. Circ. Res. 121, 803\u2013818 (2017).","journal-title":"Circ. Res."},{"key":"1183_CR96","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jchf.2024.02.012","volume":"12","author":"E Monda","year":"2024","unstructured":"Monda, E. et al. Prevalence of pathogenic variants in cardiomyopathy-associated genes in acute myocarditis: a systematic review and meta-analysis. JACC Heart Fail. 12, 1101\u20131111 (2024).","journal-title":"JACC Heart Fail."},{"key":"1183_CR97","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1161\/CIRCULATIONAHA.119.040676","volume":"140","author":"SP Chelko","year":"2019","unstructured":"Chelko, S. P. et al. Therapeutic modulation of the immune response in arrhythmogenic cardiomyopathy. Circulation 140, 1491\u20131505 (2019).","journal-title":"Circulation"},{"key":"1183_CR98","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jchf.2024.08.011","volume":"13","author":"SLVM Stroeks","year":"2025","unstructured":"Stroeks, S. L. V. M. et al. Genetic landscape of patients with dilated cardiomyopathy and a systemic immune-mediated disease. JACC Heart Fail. 13, 133\u2013145 (2025).","journal-title":"JACC Heart Fail."},{"key":"1183_CR99","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1161\/01.CIR.85.5.1734","volume":"85","author":"AL Caforio","year":"1992","unstructured":"Caforio, A. L. et al. Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 85, 1734\u20131742 (1992).","journal-title":"Circulation"},{"key":"1183_CR100","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0735-1097(02)02075-2","volume":"40","author":"A Baba","year":"2002","unstructured":"Baba, A., Yoshikawa, T. & Ogawa, S. Autoantibodies produced against sarcolemmal Na-K-ATPase: possible upstream targets of arrhythmias and sudden death in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 40, 1153\u20131159 (2002).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1183_CR101","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.010687","volume":"16","author":"E Monda","year":"2023","unstructured":"Monda, E. et al. Targeted therapies in pediatric and adult patients with hypertrophic heart disease: from molecular pathophysiology to personalized medicine. Circ. Heart Fail. 16, e010687 (2023).","journal-title":"Circ. Heart Fail."},{"key":"1183_CR102","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.123.004252","volume":"16","author":"E Monda","year":"2023","unstructured":"Monda, E. et al. Impact of GLA variant classification on the estimated prevalence of fabry disease: a systematic review and meta-analysis of screening studies. Circ. Genom. Precis. Med. 16, e004252 (2023).","journal-title":"Circ. Genom. Precis. Med."},{"key":"1183_CR103","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1093\/eurheartj\/ehae148","volume":"45","author":"M Pieroni","year":"2024","unstructured":"Pieroni, M., Namdar, M., Olivotto, I. & Desnick, R. J. Anderson\u2013Fabry disease management: role of the cardiologist. Eur. Heart J. 45, 1395\u20131409 (2024).","journal-title":"Eur. Heart J."},{"key":"1183_CR104","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia, P. et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur. Heart J. 42, 1554\u20131568 (2021).","journal-title":"Eur. Heart J."},{"key":"1183_CR105","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMra2304088","volume":"390","author":"V Sanchorawala","year":"2024","unstructured":"Sanchorawala, V. Systemic light chain amyloidosis. N. Engl. J. Med. 390, 2295\u20132307 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1183_CR106","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","volume":"128","author":"JM Griffin","year":"2021","unstructured":"Griffin, J. M., Rosenblum, H. & Maurer, M. S. Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ. Res. 128, 1554\u20131575 (2021).","journal-title":"Circ. Res."},{"key":"1183_CR107","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024947","volume":"11","author":"A Argir\u00f2","year":"2022","unstructured":"Argir\u00f2, A. et al. Sex-related differences in genetic cardiomyopathies. J. Am. Heart Assoc. 11, e024947 (2022).","journal-title":"J. Am. Heart Assoc."},{"key":"1183_CR108","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/ejhf.1216","volume":"20","author":"BP Halliday","year":"2018","unstructured":"Halliday, B. P. et al. Sex- and age-based differences in the natural history and outcome of dilated cardiomyopathy. Eur. J. Heart Fail. 20, 1392\u20131400 (2018).","journal-title":"Eur. J. Heart Fail."},{"key":"1183_CR109","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.120.003062","volume":"14","author":"NK Lakdawala","year":"2021","unstructured":"Lakdawala, N. K. et al. Associations between female sex, sarcomere variants, and clinical outcomes in hypertrophic cardiomyopathy. Circ. Genom. Precis. Med. 14, e003062 (2021).","journal-title":"Circ. Genom. Precis. Med."},{"key":"1183_CR110","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ehjqcco\/qcac006","volume":"9","author":"LR Lopes","year":"2022","unstructured":"Lopes, L. R. et al. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy\/Myocarditis Registry. Eur. Heart J. Qual. Care Clin. Outcomes 9, 42\u201353 (2022).","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"1183_CR111","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/cvr\/cvy122","volume":"114","author":"A Bondue","year":"2018","unstructured":"Bondue, A. et al. Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovasc. Res. 114, 1287\u20131303 (2018).","journal-title":"Cardiovasc. Res."},{"key":"1183_CR112","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jacc.2013.06.033","volume":"62","author":"CA James","year":"2013","unstructured":"James, C. A. et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia\/cardiomyopathy-associated desmosomal mutation carriers. J. Am. Coll. Cardiol. 62, 1290\u20131297 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1183_CR113","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012937","volume":"9","author":"ET Skj\u00f8lsvik","year":"2020","unstructured":"Skj\u00f8lsvik, E. T. et al. Exercise is associated with impaired left ventricular systolic function in patients with lamin A\/C genotype. J. Am. Heart Assoc. 9, e012937 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"1183_CR114","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599\u20133726 (2021).","journal-title":"Eur. Heart J."},{"key":"1183_CR115","doi-asserted-by":"publisher","first-page":"100843","DOI":"10.1016\/j.jacadv.2024.100843","volume":"3","author":"A Aglan","year":"2024","unstructured":"Aglan, A. et al. Impact of sodium-glucose cotransporter 2 inhibitors on mortality in hypertrophic cardiomyopathy. JACC Adv. 3, 100843 (2024).","journal-title":"JACC Adv."},{"key":"1183_CR116","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","volume":"83","author":"A Porcari","year":"2024","unstructured":"Porcari, A. et al. SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy. J. Am. Coll. Cardiol. 83, 2411\u20132422 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1183_CR117","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/ejhf.3291","volume":"26","author":"L Velicki","year":"2024","unstructured":"Velicki, L. et al. Sacubitril\/valsartan for the treatment of non-obstructive hypertrophic cardiomyopathy: an open label randomized controlled trial (SILICOFCM). Eur. J. Heart Fail. 26, 1361\u20131368 (2024).","journal-title":"Eur. J. Heart Fail."},{"key":"1183_CR118","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder, I. C. et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 45, 3314\u20133414 (2024).","journal-title":"Eur. Heart J."},{"key":"1183_CR119","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"K Zeppenfeld","year":"2022","unstructured":"Zeppenfeld, K. et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J. 43, 3997\u20134126 (2022).","journal-title":"Eur. Heart J."},{"key":"1183_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00176-5","volume":"8","author":"VJ Planelles-Herrero","year":"2017","unstructured":"Planelles-Herrero, V. J., Hartman, J. J., Robert-Paganin, J., Malik, F. I. & Houdusse, A. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil. Nat. Commun. 8, 190 (2017).","journal-title":"Nat. Commun."},{"key":"1183_CR121","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1161\/CIRCHEARTFAILURE.109.930321","volume":"3","author":"Y-T Shen","year":"2010","unstructured":"Shen, Y.-T. et al. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. Circ. Heart Fail. 3, 522\u2013527 (2010).","journal-title":"Circ. Heart Fail."},{"key":"1183_CR122","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2025797","volume":"384","author":"JR Teerlink","year":"2021","unstructured":"Teerlink, J. R. et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N. Engl. J. Med. 384, 105\u2013116 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1183_CR123","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/jama.2022.11016","volume":"328","author":"GD Lewis","year":"2022","unstructured":"Lewis, G. D. et al. Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction: the METEORIC-HF randomized clinical trial. JAMA 328, 259\u2013269 (2022).","journal-title":"JAMA"},{"key":"1183_CR124","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/ejhf.1933","volume":"22","author":"AA Voors","year":"2020","unstructured":"Voors, A. A. et al. Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. Eur. J. Heart Fail. 22, 1649\u20131658 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"1183_CR125","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04572893 (2025)."},{"key":"1183_CR126","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto, I. et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396, 759\u2013769 (2020).","journal-title":"Lancet"},{"key":"1183_CR127","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","volume":"8","author":"Z Tian","year":"2023","unstructured":"Tian, Z. et al. Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial. JAMA Cardiol. 8, 957\u2013965 (2023).","journal-title":"JAMA Cardiol."},{"key":"1183_CR128","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"MY Desai","year":"2022","unstructured":"Desai, M. Y. et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J. Am. Coll. Cardiol. 80, 95\u2013108 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1183_CR129","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","volume":"45","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia, P. et al. Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. Eur. Heart J. 45, 5071\u20135083 (2024).","journal-title":"Eur. Heart J."},{"key":"1183_CR130","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012441","volume":"18","author":"MY Desai","year":"2025","unstructured":"Desai, M. Y. et al. Mavacamten: real-world experience from 22 months of the Risk Evaluation and Mitigation Strategy (REMS) program. Circ. Heart Fail. 18, e012441 (2025).","journal-title":"Circ. Heart Fail."},{"key":"1183_CR131","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","volume":"390","author":"MS Maron","year":"2024","unstructured":"Maron, M. S. et al. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N. Engl. J. Med. 390, 1849\u20131861 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1183_CR132","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","volume":"143","author":"S Saberi","year":"2021","unstructured":"Saberi, S. et al. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis. Circulation 143, 606\u2013608 (2021).","journal-title":"Circulation"},{"key":"1183_CR133","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1016\/j.jacc.2024.08.015","volume":"84","author":"A Masri","year":"2024","unstructured":"Masri, A. et al. Effect of aficamten on cardiac structure and function in obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM CMR Substudy. J. Am. Coll. Cardiol. 84, 1806\u20131817 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1183_CR134","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","volume":"75","author":"CY Ho","year":"2020","unstructured":"Ho, C. Y. et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 75, 2649\u20132660 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1183_CR135","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05582395 (2025)."},{"key":"1183_CR136","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06081894 (2025)."},{"key":"1183_CR137","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/jamacardio.2024.3810","volume":"10","author":"SJ Shah","year":"2024","unstructured":"Shah, S. J. et al. Cardiac myosin inhibition in heart failure with normal and supranormal ejection fraction: primary results of the EMBARK-HFpEF trial. JAMA Cardiol. 10, 170\u2013175 (2024).","journal-title":"JAMA Cardiol."},{"key":"1183_CR138","doi-asserted-by":"publisher","first-page":"4142919","DOI":"10.1161\/circ.150.suppl_1.4142919","volume":"150","author":"C Emter","year":"2024","unstructured":"Emter, C. et al. Chronic administration of EDG-7500, a novel sarcomere modulator, prevents increases in cardiac mass, T1 relaxation time, and left ventricular end diastolic pressure in a Yucatan mini-pig model of genetic non-obstructive hypertrophic cardiomyopathy [abstract]. Circulation 150, 4142919 (2024).","journal-title":"Circulation"},{"key":"1183_CR139","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06347159 (2025)."},{"key":"1183_CR140","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/00005344-199503000-00018","volume":"25","author":"FM Jeffrey","year":"1995","unstructured":"Jeffrey, F. M., Alvarez, L., Diczku, V., Sherry, A. D. & Malloy, C. R. Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. J. Cardiovasc. Pharmacol. 25, 469\u2013472 (1995).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"1183_CR141","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","volume":"122","author":"K Abozguia","year":"2010","unstructured":"Abozguia, K. et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122, 1562\u20131569 (2010).","journal-title":"Circulation"},{"key":"1183_CR142","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ahj.2021.06.010","volume":"240","author":"R Ananthakrishna","year":"2021","unstructured":"Ananthakrishna, R. et al. Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial). Am. Heart J. 240, 101\u2013113 (2021).","journal-title":"Am. Heart J."},{"key":"1183_CR143","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamacardio.2018.4847","volume":"4","author":"CJ Coats","year":"2019","unstructured":"Coats, C. J. et al. Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial. JAMA Cardiol. 4, 230\u2013235 (2019).","journal-title":"JAMA Cardiol."},{"key":"1183_CR144","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jacc.2024.03.387","volume":"83","author":"MS Maron","year":"2024","unstructured":"Maron, M. S. et al. Safety and efficacy of metabolic modulation with ninerafaxstat in patients with nonobstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 83, 2037\u20132048 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1183_CR145","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/HCO.0000000000000850","volume":"36","author":"C Boada","year":"2021","unstructured":"Boada, C., Sukhovershin, R., Pettigrew, R. & Cooke, J. P. RNA therapeutics for cardiovascular disease. Curr. Opin. Cardiol. 36, 256\u2013263 (2021).","journal-title":"Curr. Opin. Cardiol."},{"key":"1183_CR146","doi-asserted-by":"publisher","first-page":"618346","DOI":"10.3389\/fgeed.2021.618346","volume":"3","author":"E Papanikolaou","year":"2021","unstructured":"Papanikolaou, E. & Bosio, A. The promise and the hope of gene therapy. Front. Genome Ed. 3, 618346 (2021).","journal-title":"Front. Genome Ed."},{"key":"1183_CR147","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1161\/CIRCRESAHA.109.202440","volume":"105","author":"S Marston","year":"2009","unstructured":"Marston, S. et al. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ. Res 105, 219\u2013222 (2009).","journal-title":"Circ. Res"},{"key":"1183_CR148","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1161\/CIRCULATIONAHA.108.838672","volume":"119","author":"SJ van Dijk","year":"2009","unstructured":"van Dijk, S. J. et al. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 119, 1473\u20131483 (2009).","journal-title":"Circulation"},{"key":"1183_CR149","first-page":"239","volume":"105","author":"N Vignier","year":"2009","unstructured":"Vignier, N. et al. Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice. CiraRes. 105, 239\u2013248 (2009).","journal-title":"CiraRes."},{"key":"1183_CR150","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00395-011-0235-3","volume":"107","author":"S Schlossarek","year":"2012","unstructured":"Schlossarek, S. et al. Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy. Basic. Res. Cardiol. 107, 235 (2012).","journal-title":"Basic. Res. Cardiol."},{"key":"1183_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6515","volume":"5","author":"G Mearini","year":"2014","unstructured":"Mearini, G. et al. Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice. Nat. Commun. 5, 5515 (2014).","journal-title":"Nat. Commun."},{"key":"1183_CR152","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.cardfail.2023.11.010","volume":"30","author":"J Haroldson","year":"2024","unstructured":"Haroldson, J. et al. MyPeak-1: a phase 1b study to evaluate safety and efficacy of TN-201, an adeno-associated virus serotype 9 (AAV9) investigational gene therapy, in adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM). J. Card. Fail. 30, S5 (2024).","journal-title":"J. Card. Fail."},{"key":"1183_CR153","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05836259 (2025)."},{"key":"1183_CR154","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05112237 (2024)."},{"key":"1183_CR155","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41591-022-02190-7","volume":"29","author":"D Reichart","year":"2023","unstructured":"Reichart, D. et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nat. Med. 29, 412\u2013421 (2023).","journal-title":"Nat. Med."},{"key":"1183_CR156","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41591-022-02176-5","volume":"29","author":"AC Chai","year":"2023","unstructured":"Chai, A. C. et al. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice. Nat. Med. 29, 401\u2013411 (2023).","journal-title":"Nat. Med."},{"key":"1183_CR157","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.omtn.2020.01.012","volume":"19","author":"BR Anderson","year":"2020","unstructured":"Anderson, B. R. et al. Allele-selective knockdown of MYH7 using antisense oligonucleotides. Mol. Ther. Nucleic Acids 19, 1290\u20131298 (2020).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1183_CR158","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1126\/science.1236921","volume":"342","author":"J Jiang","year":"2013","unstructured":"Jiang, J., Wakimoto, H., Seidman, J. G. & Seidman, C. E. Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy. Science 342, 111\u2013114 (2013).","journal-title":"Science"},{"key":"1183_CR159","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1093\/cvr\/cvac021","volume":"118","author":"J Dave","year":"2022","unstructured":"Dave, J. et al. Gene editing reverses arrhythmia susceptibility in humanized PLN-R14del mice: modelling a European cardiomyopathy with global impact. Cardiovasc. Res. 118, 3140\u20133150 (2022).","journal-title":"Cardiovasc. Res."},{"key":"1183_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25439-0","volume":"12","author":"N Grote Beverborg","year":"2021","unstructured":"Grote Beverborg, N. et al. Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy. Nat. Commun. 12, 5180 (2021).","journal-title":"Nat. Commun."},{"key":"1183_CR161","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s44161-023-00370-3","volume":"2","author":"WH Bradford","year":"2023","unstructured":"Bradford, W. H. et al. Plakophilin 2 gene therapy prevents and rescues arrhythmogenic right ventricular cardiomyopathy in a mouse model harboring patient genetics. Nat. Cardiovasc. Res. 2, 1246\u20131261 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"1183_CR162","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s44161-023-00378-9","volume":"2","author":"E Kyriakopoulou","year":"2023","unstructured":"Kyriakopoulou, E. et al. Therapeutic efficacy of AAV-mediated restoration of PKP2 in arrhythmogenic cardiomyopathy. Nat. Cardiovasc. Res. 2, 1262\u20131276 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"1183_CR163","doi-asserted-by":"publisher","first-page":"ehae666.3643","DOI":"10.1093\/eurheartj\/ehae666.3643","volume":"45","author":"M Coggins","year":"2024","unstructured":"Coggins, M. et al. Phase I gene therapy clinical trial design of RP-A601 in adult patients with PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM) [abstract]. Eur. Heart J. 45, ehae666.3643 (2024).","journal-title":"Eur. Heart J."},{"key":"1183_CR164","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06228924 (2025)."},{"key":"1183_CR165","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s43856-024-00450-w","volume":"4","author":"I Wu","year":"2024","unstructured":"Wu, I. et al. AAV9:PKP2 improves heart function and survival in a Pkp2-deficient mouse model of arrhythmogenic right ventricular cardiomyopathy. Commun. Med. 4, 38 (2024).","journal-title":"Commun. Med."},{"key":"1183_CR166","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06109181 (2025)."},{"key":"1183_CR167","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.jacc.2023.08.014","volume":"82","author":"KN Hong","year":"2023","unstructured":"Hong, K. N. et al. International consensus on differential diagnosis and management of patients with danon disease. J. Am. Coll. Cardiol. 82, 1628\u20131647 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1183_CR168","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.120.003117","volume":"13","author":"D Lotan","year":"2020","unstructured":"Lotan, D. et al. Clinical profile of cardiac involvement in danon disease: a multicenter European registry. Circ. Genom. Precis. Med. 13, e003117 (2020).","journal-title":"Circ. Genom. Precis. Med."},{"key":"1183_CR169","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1056\/NEJMoa2412392","volume":"392","author":"B Greenberg","year":"2024","unstructured":"Greenberg, B. et al. Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease. N. Engl. J. Med. 392, 972\u2013983 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1183_CR170","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06092034 (2024)."},{"key":"1183_CR171","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","volume":"77","author":"M Pieroni","year":"2021","unstructured":"Pieroni, M. et al. Cardiac involvement in Fabry disease: JACC review topic of the week. J. Am. Coll. Cardiol. 77, 922\u2013936 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1183_CR172","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann, R. et al. Enzyme replacement therapy in fabry disease a randomized controlled trial. JAMA 285, 2743\u20132749 (2001).","journal-title":"JAMA"},{"key":"1183_CR173","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng, C. M. et al. Safety and efficacy of recombinant human \u03b1-galactosidase a replacement therapy in Fabry\u2019s disease. N. Engl. J. Med. 345, 9\u201316 (2001).","journal-title":"N. Engl. J. Med."},{"key":"1183_CR174","doi-asserted-by":"publisher","first-page":"107603","DOI":"10.1016\/j.ymgme.2023.107603","volume":"139","author":"C Wanner","year":"2023","unstructured":"Wanner, C. et al. Global reach of over 20 years of experience in the patient-centered Fabry registry: advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community. Molr Genet. Metab. 139, 107603 (2023).","journal-title":"Molr Genet. Metab."},{"key":"1183_CR175","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain, D. P. et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J. Med. Genet. 52, 353\u2013358 (2015).","journal-title":"J. Med. Genet."},{"key":"1183_CR176","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1136\/heartjnl-2023-323783","volume":"110","author":"E Monda","year":"2024","unstructured":"Monda, E. et al. Incidence and risk factors for development of left ventricular hypertrophy in Fabry disease. Heart 110, 846\u2013853 (2024).","journal-title":"Heart"},{"key":"1183_CR177","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1136\/jmg-2023-109445","volume":"61","author":"EL Wallace","year":"2024","unstructured":"Wallace, E. L. et al. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. J. Med. Genet. 61, 520\u2013530 (2024).","journal-title":"J. Med. Genet."},{"key":"1183_CR178","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain, D. P. et al. Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N. Engl. J. Med. 375, 545\u2013555 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1183_CR179","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes, D. A. et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J. Med. Genet. 54, 288\u2013296 (2017).","journal-title":"J. Med. Genet."},{"key":"1183_CR180","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ymgme.2020.07.007","volume":"131","author":"U Feldt-Rasmussen","year":"2020","unstructured":"Feldt-Rasmussen, U. et al. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol. Genet. Metab. 131, 219\u2013228 (2020).","journal-title":"Mol. Genet. Metab."},{"key":"1183_CR181","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12771","volume":"48","author":"DA Hughes","year":"2025","unstructured":"Hughes, D. A. et al. Renal and multisystem effectiveness of 3.9\u2009years of migalastat in a global real-world cohort: results from the followME Fabry pathfinders registry. J. Inherit. Metab. Dis. 48, e12771 (2025).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1183_CR182","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1136\/jmg-2022-108768","volume":"60","author":"A Camporeale","year":"2023","unstructured":"Camporeale, A. et al. Effect of migalastat on cArdiac InvOlvement in FabRry DiseAse: MAIORA study. J. Med. Genet. 60, 850\u2013858 (2023).","journal-title":"J. Med. Genet."},{"key":"1183_CR183","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gim.2016.122","volume":"19","author":"ER Benjamin","year":"2017","unstructured":"Benjamin, E. R. et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet. Med. 19, 430\u2013438 (2017).","journal-title":"Genet. Med."},{"key":"1183_CR184","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ymgme.2019.04.005","volume":"127","author":"S Oommen","year":"2019","unstructured":"Oommen, S., Zhou, Y., Meiyappan, M., Gurevich, A. & Qiu, Y. Inter-assay variability influences migalastat amenability assessments among Fabry disease variants. Mol. Genet. Metab. 127, 74\u201385 (2019).","journal-title":"Mol. Genet. Metab."},{"key":"1183_CR185","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/cpt.790","volume":"103","author":"N Gu\u00e9rard","year":"2018","unstructured":"Gu\u00e9rard, N. et al. Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with fabry disease on enzyme replacement. Clin. Pharmacol. Ther. 103, 703\u2013711 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1183_CR186","doi-asserted-by":"publisher","first-page":"106963","DOI":"10.1016\/j.ymgme.2022.11.002","volume":"138","author":"PB Deegan","year":"2023","unstructured":"Deegan, P. B. et al. Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study. Mol. Genet. Metab. 138, 106963 (2023).","journal-title":"Mol. Genet. Metab."},{"key":"1183_CR187","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","volume":"3","author":"G Bianchi","year":"2021","unstructured":"Bianchi, G., Zhang, Y. & Comenzo, R. L. AL amyloidosis: current chemotherapy and immune therapy treatment strategies: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 3, 467\u2013487 (2021).","journal-title":"JACC CardioOncol"},{"key":"1183_CR188","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/FJC.0000000000001004","volume":"77","author":"M Benbrahim","year":"2021","unstructured":"Benbrahim, M., Norman, K., Sanchorawala, V., Siddiqi, O. K. & Hughes, D. A review of novel agents and clinical considerations in patients with ATTR cardiac amyloidosis. J. Cardiovasc. Pharmacol. 77, 544\u2013548 (2021).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"1183_CR189","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer, M. S. et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 379, 1007\u20131016 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1183_CR190","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","volume":"15","author":"P Elliott","year":"2022","unstructured":"Elliott, P. et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ. Heart Fail. 15, e008193 (2022).","journal-title":"Circ. Heart Fail."},{"key":"1183_CR191","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jchf.2023.08.032","volume":"12","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia, P. et al. Tafamidis efficacy among octogenarian patients in the phase 3 ATTR-ACT and ongoing long-term extension study. JACC Heart Fail. 12, 150\u2013160 (2024).","journal-title":"JACC Heart Fail."},{"key":"1183_CR192","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1161\/ATVBAHA.113.301273","volume":"33","author":"LS Hornstrup","year":"2013","unstructured":"Hornstrup, L. S., Frikke-Schmidt, R., Nordestgaard, B. G. & Tybj\u00e6rg-Hansen, A. Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy. Arterioscler. Thromb. Vasc. Biol. 33, 1441\u20131447 (2013).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1183_CR193","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2025.03.017","author":"A Masri","year":"2025","unstructured":"Masri, A. et al. Acoramidis for transthyretin amyloid cardiomyopathy: open-label extension study long-term follow-up. J. Card. Fail. https:\/\/doi.org\/10.1016\/j.cardfail.2025.03.017 (2025).","journal-title":"J. Card. Fail."},{"key":"1183_CR194","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore, J. D. et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 390, 132\u2013142 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1183_CR195","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson, M. D. et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 22\u201331 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1183_CR196","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho, T. et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA 330, 1448\u20131458 (2023).","journal-title":"JAMA"},{"key":"1183_CR197","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04136171 (2024)."},{"key":"1183_CR198","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11\u201321 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1183_CR199","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer, M. S. et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N. Engl. J. Med. 389, 1553\u20131565 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1183_CR200","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams, D. et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid 30, 1\u20139 (2023).","journal-title":"Amyloid"},{"key":"1183_CR201","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana, M. et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N. Engl. J. Med. 392, 33\u201344 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1183_CR202","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore, J. D. et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493\u2013502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1183_CR203","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06128629 (2025)."},{"key":"1183_CR204","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23274-x","volume":"12","author":"A Michalon","year":"2021","unstructured":"Michalon, A. et al. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat. Commun. 12, 3142 (2021).","journal-title":"Nat. Commun."},{"key":"1183_CR205","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2303765","volume":"389","author":"P Garcia-Pavia","year":"2023","unstructured":"Garcia-Pavia, P. et al. Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. N. Engl. J. Med. 389, 239\u2013250 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1183_CR206","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/eurheartj\/ehab895","volume":"43","author":"E Arbustini","year":"2022","unstructured":"Arbustini, E. et al. Interpretation and actionability of genetic variants in cardiomyopathies: a position statement from the European Society of Cardiology Council on cardiovascular genomics. Eur. Heart J. 43, 1901\u20131916 (2022).","journal-title":"Eur. Heart J."},{"key":"1183_CR207","doi-asserted-by":"publisher","first-page":"g6802","DOI":"10.1136\/bmj.g6802","volume":"349","author":"JJ Gagne","year":"2014","unstructured":"Gagne, J. J., Thompson, L., O\u2019Keefe, K. & Kesselheim, A. S. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ 349, g6802 (2014).","journal-title":"BMJ"},{"key":"1183_CR208","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMe030024","volume":"348","author":"SW Lagakos","year":"2003","unstructured":"Lagakos, S. W. Clinical trials and rare diseases. N. Engl. J. Med. 348, 2455\u20132456 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1183_CR209","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-024-07800-7","volume":"634","author":"M Kliegman","year":"2024","unstructured":"Kliegman, M. et al. A roadmap for affordable genetic medicines. Nature 634, 307\u2013314 (2024).","journal-title":"Nature"},{"key":"1183_CR210","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/M18-3016","volume":"170","author":"SB Heitner","year":"2019","unstructured":"Heitner, S. B. et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann. Intern. Med. 170, 741\u2013748 (2019).","journal-title":"Ann. Intern. Med."},{"key":"1183_CR211","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","volume":"81","author":"MS Maron","year":"2023","unstructured":"Maron, M. S. et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 81, 34\u201345 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1183_CR212","first-page":"1993","volume":"26","author":"A Masri","year":"2024","unstructured":"Masri, A. et al. Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: a 36-week analysis from FOREST-HCM. Eur. J. Heart Fail. 26, 1993\u20131998 (2024).","journal-title":"Eur. J. Heart Fail."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01183-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01183-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01183-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T12:03:40Z","timestamp":1757937820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01183-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":212,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1183"],"URL":"https:\/\/doi.org\/10.1038\/s41569-025-01183-6","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"assertion":[{"value":"6 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.M.E. is a consultant for Affinia, Amicus, BMS, Cytokinetics, Pfizer and Sanofi, and is the president of Cardiomyopathy UK and chairman of the International Cardiomyopathy Network. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}